Kuvan has received orphan drug designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA). Kuvan has received seven years of market exclusivity in the United States. In November 2007, Merck Serono submitted a Marketing Authorization Application (MAA) to the EMEA for sapropterin dihydrochloride as an oral treatment for patients suffering from HPA due to PKU or BH4 deficiency. If approved in the EU, it will receive 10 years of market exclusivity for this indication.
About PKU
PKU, a genetic disorder affecting approximately 50,000 diagnosed patients in the developed world, is caused by a deficiency of the enzyme phenylalanine hydroxylase. PAH is required for the metabolism of phenylalanine, an essential amino acid found in most protein-containing foods. If the active enzyme is not present in sufficient quantities, Phe accumulates to abnormally high levels in the blood and becomes toxic to the brain, resulting in a variety of complications including severe mental retardation and brain damage, mental illness, seizures, tremors, and limited cognitive ability. To learn more about PKU, please visit http://www.PKU.com.
About Fairview Specialty Pharmacy
Fairview Specialty Pharmacy provides personal medication management
services to patients who take high-cost or self-injected drugs for chronic
conditions. Fairview Specialty Pharmacy ensures that patients receive their
medications safely and on time via services including medication management
and monitoring, free shipping anywhere in the US, and monthly refill
reminder phone calls. All calls are answered by "live" pha
'/>"/>
| SOURCE Fairview Specialty Pharmacy Copyright©2008 PR Newswire. All rights reserved |